171 related articles for article (PubMed ID: 17569592)
1. Therapeutic erythrocytapheresis versus phlebotomy in the initial treatment of hereditary hemochromatosis - A pilot study.
Rombout-Sestrienkova E; van Noord PA; van Deursen CT; Sybesma BJ; Nillesen-Meertens AE; Koek GH
Transfus Apher Sci; 2007 Jun; 36(3):261-7. PubMed ID: 17569592
[TBL] [Abstract][Full Text] [Related]
2. In hereditary hemochromatosis, red cell apheresis removes excess iron twice as fast as manual whole blood phlebotomy.
Muncunill J; Vaquer P; Galmés A; Obrador A; Parera M; Bargay J; Besalduch J
J Clin Apher; 2002; 17(2):88-92. PubMed ID: 12210712
[TBL] [Abstract][Full Text] [Related]
3. Erythrocytapheresis versus phlebotomy in the initial treatment of HFE hemochromatosis patients: results from a randomized trial.
Rombout-Sestrienkova E; Nieman FH; Essers BA; van Noord PA; Janssen MC; van Deursen CT; Bos LP; Rombout F; van den Braak R; de Leeuw PW; Koek GH
Transfusion; 2012 Mar; 52(3):470-7. PubMed ID: 21848963
[TBL] [Abstract][Full Text] [Related]
4. Patient compliance with phlebotomy therapy for iron overload associated with hemochromatosis.
Hicken BL; Tucker DC; Barton JC
Am J Gastroenterol; 2003 Sep; 98(9):2072-7. PubMed ID: 14499790
[TBL] [Abstract][Full Text] [Related]
5. Hepatic iron concentration in hereditary hemochromatosis does not saturate or accurately predict phlebotomy requirements.
Olynyk JK; Luxon BA; Britton RS; Bacon BR
Am J Gastroenterol; 1998 Mar; 93(3):346-50. PubMed ID: 9517637
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of phlebotomy to reduce transfusional iron overload in adult, long-term survivors of acute leukemia.
Franchini M; Gandini G; Veneri D; de Matteis G; Federici F; Solero P; Aprili G
Transfusion; 2004 Jun; 44(6):833-7. PubMed ID: 15157247
[TBL] [Abstract][Full Text] [Related]
7. Erythrocytapheresis versus phlebotomy in the maintenance treatment of HFE hemochromatosis patients: results from a randomized crossover trial.
Rombout-Sestrienkova E; Winkens B; Essers BA; Nieman FH; Noord PA; Janssen MC; van Deursen CT; Boonen A; Reuser-Kaasenbrood EP; Heeremans J; van Kraaij M; Masclee A; Koek GH
Transfusion; 2016 Jan; 56(1):261-70. PubMed ID: 26358375
[TBL] [Abstract][Full Text] [Related]
8. [Erythrocytapheresis for hereditary haemochromatosis].
Rombout-Sestrienkova E; van Deursen CT; Janssen MC; van Kraaij MG; de Leeuw PW; Koek GH
Ned Tijdschr Geneeskd; 2012; 156(26):A4745. PubMed ID: 22759710
[TBL] [Abstract][Full Text] [Related]
9. The efficiency of therapeutic erythrocytapheresis compared to phlebotomy: a mathematical tool for predicting response in hereditary hemochromatosis, polycythemia vera, and secondary erythrocytosis.
Evers D; Kerkhoffs JL; Van Egmond L; Schipperus MR; Wijermans PW
J Clin Apher; 2014 Jun; 29(3):133-8. PubMed ID: 24130064
[TBL] [Abstract][Full Text] [Related]
10. Effect of phlebotomy on lipid metabolism in subjects with hereditary hemochromatosis.
Casanova-Esteban P; Guiral N; Andrés E; Gonzalvo C; Mateo-Gallego R; Giraldo P; Paramo JA; Civeira F
Metabolism; 2011 Jun; 60(6):830-4. PubMed ID: 20846699
[TBL] [Abstract][Full Text] [Related]
11. Course of iron parameters in HFE-hemochromatosis patients during initial treatment with erythrocytapheresis compared to phlebotomy.
Rombout-Sestrienkova E; Koek GH; Neslo R; van Kraaij M; Menheere PP; Masclee A; Swinkels DW
J Clin Apher; 2016 Dec; 31(6):564-570. PubMed ID: 26878994
[TBL] [Abstract][Full Text] [Related]
12. Repeated isovolemic large-volume erythrocytapheresis in the treatment of idiopathic hemochromatosis.
Kellner H; Zoller WG
Z Gastroenterol; 1992 Nov; 30(11):779-83. PubMed ID: 1471384
[TBL] [Abstract][Full Text] [Related]
13. [Predictive factors of response to erytrhocytapheresis in patients with biochemical iron overload with or without hereditary hemochromatosis type 1].
Parra Salinas I; Montes Limon A; Recasens Flores V; Fernandez-Mosteirin N; Garcia-Erce JA
Med Clin (Barc); 2014 Mar; 142(5):187-91. PubMed ID: 24041941
[TBL] [Abstract][Full Text] [Related]
14. Patients with hereditary hemochromatosis reach safe range of transferrin saturation sooner with erythrocytaphereses than with phlebotomies.
Rombout-Sestrienkova E; Brandts L; Koek GH; van Deursen CTBM
J Clin Apher; 2022 Feb; 37(1):100-105. PubMed ID: 34897777
[TBL] [Abstract][Full Text] [Related]
15. [Comparison between phlebotomy and erythrocytapheresis of iron overload in patients with HFE gene mutations].
Fernández-Mosteirín N; Salvador-Osuna C; García-Erce JA; Orna E; Pérez-Lungmus G; Giralt M
Med Clin (Barc); 2006 Sep; 127(11):409-12. PubMed ID: 17020684
[TBL] [Abstract][Full Text] [Related]
16. Hereditary hemochromatosis: a case study and review.
Laudicina RJ; Legrys VA
Clin Lab Sci; 2001; 14(3):196-208; quiz 220-2. PubMed ID: 11517631
[TBL] [Abstract][Full Text] [Related]
17. Soluble transferrin receptor in hemochromatosis patients during phlebotomy therapy.
Piéroni L; Mekhloufi F; Thiolières JM; Hainque B; Herson S; Jardel C
Clin Chim Acta; 2005 Mar; 353(1-2):61-6. PubMed ID: 15698591
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic erythrocytapheresis in the initial treatment of hereditary hemochromatosis.
Rehácek V; Bláha M; Jirousová H; Cernohorská J; Papousek P
Acta Medica (Hradec Kralove); 2012; 55(4):180-5. PubMed ID: 23631289
[TBL] [Abstract][Full Text] [Related]
19. Hereditary hemochromatosis: patient experiences of the disease and phlebotomy treatment.
Brissot P; Ball S; Rofail D; Cannon H; Jin VW
Transfusion; 2011 Jun; 51(6):1331-8. PubMed ID: 21175649
[TBL] [Abstract][Full Text] [Related]
20. A predictive model for estimating the number of erythrocytapheresis or phlebotomy treatments for patients with naïve hereditary hemochromatosis.
Rombout-Sestrienkova E; Winkens B; van Kraaij M; van Deursen CTBM; Janssen MCH; Rennings AMJ; Evers D; Kerkhoffs JL; Masclee A; Koek GH
J Clin Apher; 2021 Jun; 36(3):340-347. PubMed ID: 33368569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
